Derek Jeter's Media Platform on Facebook's New News Feed
Facebook's decision to change what posts are featured in users' news feeds has some media publishers worried their content won't reach the intended audience.
But the CEO of a platform founded by Derek Jeter thinks the new algorithms will actually benefit his company.
"We are a super high quality, premium publisher of very insightful stories that people want to talk about and people want to share with their friends," said Jeff Levick, chief executive at The Players' Tribune.
"I think that's exactly what the intention behind the Facebook change is meant to be. It's to favor and encourage real authentic, thoughtful content that resonates with their audience."
Facebook last week announced it would stop emphasizing content from third-party publishers and brands, instead focusing on posts shared by friends and family.
And Levick thinks posts on The Players' Tribune fit that bill.
The site, which started in 2014, allows professional athletes to create videos, podcasts, and text articles themselves and share that content with their fans.
NBA star Kevin Durant took to the platform in 2016 to announce he was leaving the Oklahoma City Thunder for Golden State. And Isaiah Thomas debuted his own docu-series on the platform in November.
For the full interview, [click here](https://cheddar.com/videos/the-players-tribune-giving-a-voice-and-pen-to-pro-athletes).
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d